Objective To evaluate the early diagnosis and prognosis ofmultiple myeloma (MM) by gene sequencing technology. Methods 68 patientswith MM admitted from May 2020 to May 2024 were randomly divided intoobservation group (34 cases) and control group (34 cases). Patients inthe observation group received early diagnosis and prognosis assessmentrelated to gene sequencing, while those in the control group receivedtraditional diagnosis methods. Results In the early diagnosis accuracy,the number of correct and wrong diagnoses in the observation group was31 cases and 3 cases, respectively, and the diagnosis accuracy was91.2%. The number of correct and wrong diagnoses in control group was 23cases and 11 cases, respectively, the diagnostic accuracy was ${67.62}\%$ , and the observation group washigher $\left({P <{0.05}}\right)$ .In the observation group, the number of ISS stage I, ISS Stage II, ISSStage III and high-risk mutation detection were 10 cases, 15 cases, 9cases and 12 cases, respectively, and the accuracy of prognosisassessment was 85.3%. In the control group, there were 8 cases of ISSstage I, 13 cases of ISS stage II, 13 cases of ISS stage III and 8 casesof high-risk mutation detection, respectively. The accuracy of prognosisassessment was ${67.6}\%$ , and theaccuracy of prognosis assessment in the observation group wassignificantly higher than that in the control group. The overallsurvival rate and progression-free survival rate were 94.1% and 70.6% inthe observation group, and 82.4% and 52.9% in the control group,respectively, which were higher in the observation group $\left({P <{0.05}}\right)$ . Conclusion Gene sequencing technology is helpful to the early detection of MM andthe formulation of personalized treatment plan, improve the survivalrate and quality of life of patients, and has the value of applicationand promotion in clinical practice.

multiple myeloma  /  gene sequencing  /  early diagnosis  /  prognosis assessment